drugset
drugset / Trial / NCT06504368

Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors

NCT06504368 ↗

Phase 1 Recruiting 32 enrolled Dicerna Pharmaceuticals, Inc.
NaSequentialOpen-labelTreatment

Summary

The study will evaluate the safety, tolerability, and pharmacokinetics of intravenous DCR-PDL1 in adults with solid tumors. Participants will be enrolled in one of 4 ascending-dose cohorts. Each treatment cycle will consist of multiple intravenous (IV) doses. Dose escalation decisions will be based on data collected during the dose-limiting toxicity (DLT) period.

Timeline

Start
2024-05-29
Primary completion
2026-06-01
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject DCR-PDL1 Unknown — Intravenous

Indications

No indication recorded.